Nick Pizzie is CFO at Axsome Therapeutics, Inc. (AXSM). They have made 7 open-market trades across 1 company since 2018, most recently 2026-06-09.
CIK 0001742143
6 open-market purchases totalling $478K since 2018, against 1 sale. Across 6 scored buys the stock is up 80.5% at ninety days, and 77.2 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AXSM | 42,867 | $6.7M |
Shares reported on the most recent Form 4, priced at the 2026-06-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 67% | 67% |
| Avg Move | -4.2% | +5.8% | +80.5% |
| Alpha | -3.9% | +3.3% | +77.2% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AXSM | SELL · 10b5-1 | 2026-06-09 | 2026-06-09 | $240.09 | $7.9M | -1.3% | -0.9% | -17.3% |
| AXSM | SELL | 2026-01-22 | 2026-01-23 | $187.92 | $2.3M | +0.6% | -5.2% | -0.9% |
| AXSM | SELL · 10b5-1 | 2025-02-13 | 2025-02-14 | $129.99 | $3.5M | +1.4% | +0.8% | -14.0% |
| AXSM | BUY | 2021-11-18 | 2021-11-22 | $35.26 | $34K | -13.4% | +1.2% | -23.6% |
| AXSM | BUY | 2020-06-29 | 2020-06-30 | $76.64 | $119K | -6.8% | -9.4% | -7.2% |
| AXSM | BUY | 2019-09-26 | 2019-09-30 | $24.80 | $54K | -13.0% | +12.7% | +412.7% |
| AXSM | BUY | 2019-06-11 | 2019-06-12 | $20.80 | $40K | +5.5% | +17.1% | +10.7% |
| AXSM | BUY | 2019-03-19 | 2019-03-21 | $12.58 | $135K | +2.3% | +13.0% | +85.6% |
| AXSM | BUY | 2018-06-19 | 2018-06-20 | $3.10 | $96K | +0.0% | +0.0% | +4.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.